Solid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients

Ann Marie Liapakis*, Richard N. Formica, Josh Levitsky

*Corresponding author for this work

Research output: Contribution to journalReview article

9 Scopus citations

Abstract

Purpose of review Strategies are needed to reduce waitlist mortality and increase transplantation rates. Advances in hepatitis C therapy has allowed the transplant community to look toward utilization of grafts from hepatitis C viremic donors to expand the organ pool. Use of such grafts for hepatitis C-negative patients is being evaluated and debated, and early trial data are emerging. Recent findings Both hepatitis C antibody-positive/nucleic acid test-negative and viremic donors are currently underutilized. Outcomes for viral hepatitis C (HCV) viremic transplant recipients are improving in the setting of direct-acting antiviral therapy. Optimization of graft utilization from HCV ‘positive’ donors and expansion to use of viremic donors for HCV-negative recipients will likely reduce waitlist mortality and result in net overall reduction in healthcare expenditures. Summary Herein, we provide a review of recent advancements relating to hepatitis C in solid organ transplant and outline future directions. A primary future focus will be data collection of outcomes of transplantation of grafts from HCV ‘viremic’ donors to nonviremic recipients in formal clinical trial protocols.

Original languageEnglish (US)
Pages (from-to)257-263
Number of pages7
JournalCurrent opinion in organ transplantation
Volume23
Issue number2
DOIs
Publication statusPublished - Jan 1 2018

    Fingerprint

Keywords

  • Donor transmission
  • Hepatitis C
  • Nucleic acid testing
  • Solid organ transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation

Cite this